Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Smith & Nephew Snats ( (SNN) ).
On August 12, 2025, Smith & Nephew plc announced the partial vesting of share awards under its Global Share Plan 2020. These awards, initially granted on August 11, 2023, will vest in equal tranches over three years. The recent vesting led to some shares being sold to cover tax obligations, impacting the company’s share distribution and potentially influencing stakeholder perceptions of executive compensation strategies.
The most recent analyst rating on (SNN) stock is a Hold with a $27.27 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
Smith & Nephew Snats shows strong financial performance and positive earnings call sentiment, driving the overall score. Technical indicators suggest a strong upward trend, though the stock appears overbought. Valuation metrics indicate potential overvaluation, which slightly tempers the overall score.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith & Nephew plc is a global medical technology company that specializes in advanced wound management, orthopedics, and sports medicine. The company focuses on providing innovative solutions to improve patient outcomes and is listed on the London Stock Exchange.
Average Trading Volume: 963,548
Technical Sentiment Signal: Buy
Current Market Cap: $15.87B
For an in-depth examination of SNN stock, go to TipRanks’ Overview page.